Comparison of Post-Therapy 4 and 24-hour [177Lu]Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer.

Mina Swiha[1,2], Sarennya Pathmanandavel[1], Nathan Papa[3], Zahra Sabahi[1], Sherrington Li[1], Alex Zheng[1], Sobia Khan[1], Maria Ayers[1], Shikha Sharma[1], Megan Crumbaker[1,3,4], Andrew Nguyen[1,4], Lyn Chan[1], Narjess Ayati[1,3,4], Louise Emmett[1,3,4]

1. Department of Theranostics and Nuclear medicine, St Vincent's Hospital Sydney, Australia
2. Molecular Imaging and Theranostics Division, Department of Medical Imaging, University of Western Ontario, London, Canada 3. Garvan Institute of Medical Research, Sydney, Australia 4. St Vincent's Clinical School, University of New South Wales, Sydney, Australia

No disclosures

BACKGROUND

- [^{177}Lu]Lu-PSMA is an effective treatment for metastatic castrate-resistant prostate cancer (mCRPC).

- Studies have confirmed the ability of [^{177}Lu]Lu-PSMA SPECT/CT at 24 and 48 hours to predict response to [^{177}Lu]Lu-PSMA as early as of 6 weeks (1-3).

[1] Emmett L, et al. Ther Adv Med Oncol. 2023;15:17588359231156392.
[2] John N, et al. J Nucl Med. 2023;64:410-415.
[3] Neubauer MC, et al. Eur J Nucl Med Mol Imaging. 2024;51:1185-1193.

AIM

- However, SPECT/CT at 24 hours post therapy can be inconvenient for patients requiring overnight stay for rural/distant patients.

- The aim of this study was to evaluate the 4-hour [^{177}Lu]Lu-PSMA SPECT/CT as an alternative to 24-hour [^{177}Lu]Lu-PSMA SPECT/CT for evaluation of treatment response.

METHODS

- Prospective ethics approved pilot study.

- 23 men with mCRPC treated with [^{177}Lu]Lu-PSMA-I&T between May and November 2023 (HREC 2022/ETH00924).

Inclusion criteria

- [^{68}Ga]Ga-PSMA-11 PET/CT(SUVmax ≥ 15 and SUVmax ≥10 at all the measurable lesions(> 2cm))

- mCRPC post ARPI and taxane chemotherapy or unfit for taxane.

- Eastern Cooperative Oncology Group (ECOG) ≤ 2.

METHODS

- Post-therapy SPECT/CT (Discovery NM/CT 870 DR, GE Healthcare) acquired at 4- and 24-hours after the first dose and 4 hours following the second dose.

  ✓ Vertex to mid-thigh

  ✓ 3 fields of view,

  ✓ 10s/frame

  ✓ Energy window 208 keV ± 10%

  ✓ Scatter window 165 keV ± 6.5%.

METHODS

- Acquisition time was 25 minutes at each timepoint.

- Reconstruction of SPECT projections performed with an iterative ordered subset expectation maximization (OSEM) algorithm using 4 iterations and 10 subsets.

METHODS

Standard dose 8.5 GBq [^{177}Lu]Lu-PSMA-I&T prior to SPECT/CT imaging timepoints.

2/23 patients excluded (incomplete imaging data).

Baseline [^{68}Ga]Ga-PSMA-11 PET/CT, 4-hour, and 24-hour [^{177}Lu]Lu-PSMA SPECT/CT were analyzed visually and semi-quantitatively.

Visual analysis assessed lesion number, size and site (organ based).

METHODS

Quantitative analysis performed using (LesionID; MIM Software Inc.) to derive standardized uptake value (SUV)mean, SUVmax and total tumor volume (TTV).

Moreover, quantitative analysis of the change in the total tumor volume (Δ Volume) on the 4-hour [^{177}Lu]Lu-PSMA SPECT/CT after the first and second doses was correlated to patient outcomes.

RESULTS

Characteristic	Value (n = 21)
Age at first [^{177}Lu]Lu-PSMA cycle, years	78 (70-81)
ECOG Status	
0-1	14 (67)
2	7 (33)
Baseline PSA, ng/ml	54 (15-510)
eGFR ml/min/1.73m^2	83 (71-90)
Previous Systemic Treatments	
ARPI	21 (100%)
Docetaxel	11 (52%)
Cabazitaxel	5 (24%)

PATIENTS CHARACTERSTICS

Duration between PSMA-PET/CT and first [¹⁷⁷Lu]Lu-PSMA I&T cycle	34 (24-37)
Disease Volume (PSMA-PET/CT)	
<20 metastases	7 (33)
≥ 20 metastases	14 (67)
Sites of Disease	
Bone	19 (90)
Nodal (pelvic and/or distant)	12 (57)
Visceral	4 (19)

RESULTS

- Disease distribution was unchanged between the 4-hour, 24-hour [177Lu]Lu-SPECT/CT and screening [68Ga]Ga-PSMA-11 PET/CT.

RESULTS

Visually the background activity was higher on the 4-hour [^{177}Lu]Lu-PSMA SPECT/CT compared to 24-hour [^{177}Lu]Lu-PSMA SPECT/CT and [^{68}Ga]Ga-PSMA PET/CT.

Baseline ^{68}Ga-PSMA PET/CT   4 h ^{177}Lu-PSMA SPECT/CT   24 h ^{177}Lu-PSMA SPECT/CT

Baseline ^{68}Ga-PSMA PET/CT   4 h [177]Lu- PSMA SPECT/CT   24 h [177]Lu- PSMA SPECT/CT

RESULTS

- 52% (11/21) patients had few small missed lesions on 4-hour [^{177}Lu]Lu-PSMA SPECT/CT compared to 24-hour [^{177}Lu]Lu-PSMA SPECT/CT.

- Median number of missed lesions 1(IQR 0-1) and all (< 2cm). The median SUVmax of the missed lesions is 5 (IQR 4-8).

- 75% of the missed lesions were osseous, and 25% nodal lesions. No visceral lesions were missed.

Baseline ^{68}Ga-PSMA PET/CT   4 h ^{177}Lu- PSMA SPECT/CT   24 h ^{177}Lu- PSMA SPECT/CT

RESULTS

- 67% (14/21) of patients had lesions not identified on both 4-hour and 24-hour [^{177}Lu]Lu-SPECT/CT compared with [^{68}Ga]Ga-PSMA PET/CT.

- The median number of missed lesions on post-therapy [^{177}Lu]Lu-PSMA SPECT/CT at 4 hours compared to the reference [^{68}Ga]Ga-PSMA PET/CT was 3 (IQR 0-5).

- All missed lesions were small (< 2 cm)

$\rho_c = 0.988$ $\rho_c = 1.0$ $\rho_c = 0.988$ $\rho_c = 0.988$

RESULTS

- TTV, number of lesions, SUVmax, SUVmean concordance correlation between 4-hour and 24-hour SPECT/CT was almost perfect to substantial.

RESULTS

- The mean difference in number of lesions, SUVmax and SUVmean was not statistically significant. While the mean difference shows higher variation at smaller TTV.

RESULTS

- Of the 7 patients with Δ TTV > -30%, 2 achieved PSA-50 (29%), versus 10 out of 13 (77%) with Δ TTV ≤ -30%.

- There were 13 patients with PSA progression or death recorded by July 2024. The median time from cycle 2 was 3.9 months overall, 1.8 months in those with < 30% reduction in TTV, and 8.2 months with ≥ 30% reduction in TTV.

CONCLUSION

- 4-hour [^{177}Lu]Lu-PSMA SPECT/CT appears of sufficient quality and reproducibility for clinical use and appears a reasonable alternative to 24-h SPECT/CT .

- It is important to use the same post injection timepoint (either 4 or 24 hours) for serial analysis of total tumor volume due to variation at low tumor volumes between the 4- and 24-hour images.

- The change in TTV (Δ Volume) between dose 1 and 2 [^{177}Lu]Lu-PSMA SPECT/CT predicted PSA-50 and PSA progression-free survival.

THANK YOU